الصفحة الرئيسية>>Signaling Pathways>> GPCR/G protein>> Leukotriene Receptor>>LTD4 antagonist 1

LTD4 antagonist 1

رقم الكتالوجGC31944

مضاد LTD4 1 هو مناهض قوي ونشط عن طريق الفم من leukotriene D4 (LTD4) مع Ki يبلغ 0.57 نانومتر

Products are for research use only. Not for human use. We do not sell to patients.

LTD4 antagonist 1 التركيب الكيميائي

Cas No.: 136564-67-5

الحجم السعر المخزون الكميّة
1mg
1176٫00
متوفر
5mg
2354٫00
متوفر
10mg
3998٫00
متوفر
20mg
7060٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LTD4 antagonist 1 is a potent, orally active antagonist of leukotriene D4 (LTD4) with a Ki of 0.57 nM.

LTD4 antagonist 1 (Compound 38b) exhibits a Ki of 0.57 nM for displacement of [3H]LTD4 on guinea pig lung membranes, a pKB of 9.93±0.14 versus LTE4 on guinea pig trachea[1].

LTD4 antagonist 1 (Compound 38b) exhibits a po ED50/iv ED50 of 1.44 and 0.036 μmol/kg in LTD4-induced bronchoconstriction in guinea pigs[1].

[1]. Robert T. Jacobs, et al. Synthesis, Structure-Activity Relationships, and Pharmacological Evaluation of a Series of Fluorinated 3-Benzyl-5-Indolecarboxamides: Identification of 4-[[5-[((2R)-2-Methyl-4,4,4-trifluorobutyl)carbamoyl]-1-methylindol-3-yl]methyl]-3methoxy-N-[(2-methylphenyl)sulfonyl]benzamide, a Potent, Orally Active Antagonist of Leukotrienes D4 and E4. Journal of Medicinal Chemistry (1994), 37(9), 1282-97.

مراجعات

Review for LTD4 antagonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LTD4 antagonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.